EBSAM
EGRX

Eubel Brady & Suttman Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2
Closed – – 370
2021
Q2 		$0 Buy
+2
New +$83 ﹤0.01% 672

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's EGRX Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2021, closing a stake of 2 shares.

Eubel Brady & Suttman Asset Management first reported a position in EGRX in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 151 funds tracked by Wall St. Rank hold EGRX as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 2 Eagle Pharmaceuticals, Inc. shares in Q3 2021.
  • Eubel Brady & Suttman Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $0 in Q2 2021.
  • 151 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.